Survivin (SVV), an inhibitor of apoptosis protein, is found to be upregulated in many cancers. We previously demonstrated that a dominant-negative mutant SVV-D53A was able to induce apoptosis in a p53-independent manner. Here, we report the construction and characterization of a recombinant replication-deficient adenoviral vector encoding a human SVV-D53A gene for its effectiveness against tumor growth both in vitro and in vivo. Transfection of liver tumor cells QGY-7703 with Ad-SVV-D53A results in significant apoptosis as measured by an increase in sub-G1 DNA content, procaspase-9 activation and further downstream PARP-1 cleavage. Furthermore, animal studies using QGY-7703 liver carcinoma xenografts in nude mice revealed that treatment of QGY-7703 cells with dominant-negative SVV-D53A, but not with wild-type SVV-adenovirus, prevents tumor outgrowth, inhibits growth of established tumors and results in a notably improved survival advantages in xenograft studies. Both the transferase-mediated dUTP nick-end labeling assay and immunostaining experiment demonstrated that tumor growth inhibition is associated with apoptosis induced by SVV-D53A expression. Taken together, these data suggest that recombinant adenovirus Ad-SVV-D53A carrying a Survivin dominant-negative gene SVV-D53A promotes apoptosis-mediated tumor suppression and could potentially be a promising candidate for cancer therapies.
Introduction
It has been more than three decades since apoptosis was first described as a genetically controlled programmed cellular suicide process. 1, 2 Apoptosis is essential for shaping the developing organism during embryonic growth, removing superfluous or outdated structures. 3 Two main families of apoptosis regulators have been identified, one is the Bcl-2 family, which comprises molecules with either pro-or antiapoptotic functions, and the other is the family of inhibitor of apoptosis proteins (IAPs). 4 In human beings, eight members of the IAP gene family have been identified -including the most studied molecules such as XIAP, c-IAP1, c-IAP2 and Survivin. 5 The bcl-2 family proteins have been implicated mainly in the control of mitochondrial homeostasis, most notably cytochrome c and/or Smac/DIABLO release, whereas the members of the IAPs control a downstream step in cell death by suppressing the processing of the catalytic activity of caspases, the main executioners of cell death programs. 6 We constructed a recombinant replicationdeficient adenovirus encoding a Survivin dominantnegative mutant SVV-Asp53Ala, which significantly blocks proliferation of tumor cells by inducing apoptosis of the transducted cells. Although some data obtained from studies on the Survivin and its mutants in the preclinical research have been reported, the proven effectiveness of Survivin's treatment for tumor therapy has yet to be verified. 7, 8 Over the past few years, mutational analysis of Survivin has helped provide some insightful clues in characterizing the function of Survivin and dissecting its downstream signaling events. 9 Identification of a novel mutant that could reverse the antiapoptotic function of wild-type (wt) Survivin could provide alternative contribution to induce the apoptosis of tumor cells. We previously demonstrated that Survivin dominant-negative mutant SVV-D53A was able to induce apoptosis due to the loss of its ability to interact with Smac/DIABLO. 10 Moreover, SVV-D53A promotes apoptosis in a p53-independent fashion, which triggered us to construct a recombinant adenoviral vector expressing SVV-D53A to test whether it is able to effectively induce apoptosis and suppress both the tumor development and tumor growth in vivo. The advantage of using adenoviruses for gene therapy as opposed to retroviruses is the ability to induce high levels of protein expression in a wide range of cell types, including nondividing cells. 11 Here, we demonstrate that recombinant adenoviral vector Ad-SVV-D53A carrying SVV-D53A gene caused significant apoptosis in QGY-7703 hepatocarcinoma cells, through mitochondrial apoptotic pathway. When transducted with Ad-SVV-D53A, potent tumorigenic cells QGY-7703 are no longer able to develop experimental tumor xenografts in BALB/c nude mice, indicating that SVV-D53A-mediated-apoptosis seen in vitro is also likely to work well in an in vivo situation. Furthermore, we demonstrated that intratumoral injection of Ad-SVV-D53A efficiently suppressed the implanted tumor growth and intraperitoneal (i.p.) administration of Ad-SVV-D53A significantly extended the life span of i.p. tumorbearing mice.
Materials and methods

Reagents and antibodies
Pme I and Pac I were purchased from New England Biolabs Ltd (UK). Both pAdTrack-CMV and pAdEasy-1 vectors were purchased from Qbiogene. Lipofectamine 2000 was from Invitrogen. Polyclonal antibodies Survivin and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); Monoclonal antibodies mAb-caspase-9 and mAb-Flag were from R&D systems Inc. Polyclonal PARP antibody was purchased from NeoMarkers (Baesweiler, Germany). Cell Apoptosis Detection Kit transferasemediated dUTP nick-end labeling (TUNEL) was from Promega. Most of the chemicals and reagents used in this study were ordered from Sigma unless otherwise specified.
Cell cultures QGY-7703 and HeLa cell lines were purchased from Shanghai Institute of Life Sciences, Chinese Academy of Sciences (PR China). 293A cell line was purchased from Qbio-gene. A549, H1299 and H460 were purchased from ATCC. LNCAP and DU145 were kindly gifted by Professor Ronald Rodriguez (Johns Hopkins University, School of Medicine). Primary human fibroblast cells HF-B from 12-week gestation fetus was kindly provided by Dr Xinyu Wang in Anhui Medical University. Human spontaneously transformed endothelial cell line ECV304 was a gift from Professor Jin Liu (University of Science and Technology of China). Cell lines were grown and maintained according to the instructions provided by the suppliers.
Purification of viral particles by banding on CsCl 293A cells cultured in T-75 flask at approximately 80% confluence were replaced with medium complemented with 2% (v/v) fetal bovine serum (FBS) and inoculated with adenovirus at multiplicity of infection (MOI) 5:1. When cytopathic effect occurred after 48-72 h, the transducted cells were harvested and washed twice with phosphate buffer saline (PBS) (pH7.4) and resuspended in 10 ml of PBS buffer. Adenoviruses were made to release from the transducted cells by three freeze-thaw cycles. After a high-speed centrifugation at 15 000 g for 20 min at 41C, the supernatant containing the viral particles was collected. Cesium chloride was added to the supernatant at a density of 1.35 g/ml and followed by spin in SW28 rotor with 28 000 r.p.m. at 101C for 18 h. 12 Viral fraction that appeared as a thin band was collected with a 5 cc syringe and after dialysis viruses were purified by passing through a 0.2 mm filter and stored at À701C for future use. All three viruses were made by the same procedure.
BALB/cA-nu mice and tumor implantations Four to six-week-old athymic BALB/c nude female mice, weighing approximately 14 g were obtained from the Shanghai Slaccas Animal Company, China. Mice were quarantined for a minimum of 5 days in the SPF Grade Animal House under a 12 h light/dark cycles at 24-251C with a relative humidity of 50-55% conditions. Institutional guidelines were followed in handling the animals. Tumors were established by subcutaneously (s.c.) or i.p. injection with QGY-7703 cells (4 Â 10 6 ) either in the flanks or in peritoneal region of the animals.
Replication-competent adenovirus assay
Replication-competent adenovirus (RCA) was initially analyzed by the polymerase chain reaction using purified virus as template with primers flanking the region of E1A from 416 to 585 bp: sense primer: 5 0 CGTTCCGGGTCA AAGTTGG 3 0 ; antisense primer: 5 0 CCTCCGTGGCA GATAATATGTC 3 0 . Briefly, the purified adenoviruses were diluted at 1:10 in the ddH 2 O (final volume 30 ml) and boiled for 5 min at 951C, 1 ml from which was used as a template to amplify E1A. Replication-competent adenovirus assay was also performed in vivo using HeLa and 293A cells subsequently. HeLa cells were first transducted by adenoviruses (10 MOI) and the media were changed 6 h post-transfection. Three days later, supernatant from the transducted HeLa cells was added to a fresh monolayer of 293A cells and incubated for 72 h. Green fluorescent protein expression in 293A cells was taken as an indication of the presence of RCA. 9, 13, 14 Flow cytometry and Western blot analysis Flow cytometry was performed to analyze DNA content by PI staining. Cells (2 Â 10 6 ) transducted with adenoviruses were collected at 24, 36 and 72 h post-transfection, washed once with PBS and fixed in 70% ethanol (1 h, 41C). Cells were then washed twice in PBS containing 0.5% Tween-20 and incubated in 1 ml of 0.1 N HCl/0.7% Triton X-100 for 10 min at 41C. After washing with 5 ml of PBS, the samples were finally suspended in 0.3 ml of binding buffer with 250 ng/ml propidium iodide (PI) and 40 mg/ml RNase A. After incubating at 41C for at least 0.5 h analysis was performed on Becton Dickinson (Mountain View, CA) FACScan Flow Cytometer using the Cellquest program (Becton Dickinson). Ten thousand events were analyzed for each analysis. Western blotting was performed as described previously. 15 Measurement of cell viability 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was used to assess cell viability. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays were carried out in 96-well plates. About 5 mg/ml MTT was added to each well following adenovirus treatments. The volume of MTT added was equal to one-tenth of the total volume of the well. After 3 h incubation at 371C, 100 ml dimethylsulfoxide (DMSO) was added to culture medium, and plates were then removed and read in triplicate at 570 and 630 nm, respectively, as test and reference wavelengths.
Monitoring of efficiency of adenovirus transfection in vitro and in vivo
The transfection efficiency in vitro was presented by the percentages of green cells seen under fluorescence microscope. At MOI of 50, approximately 100% of all the tested cell lines were transducted. Whereas with the MOI of 10, the number of GFP-positive cells can be reached to 50-80% among the different cell lines tested. To monitor the ability of adenovirus to transduce the target cells in vivo, the nude mice bearing early and later stages of s.c. tumors were treated with adenovirus intratumorally (2.5 Â 10 7 GFU/100 ml), 48 h postinjection, the nude mice were killed, and frozen tumor tissue section slides were observed under the fluorescence microscope seeking the expression of GFP. Transfection efficiency of adenovirus-mediated gene transfer to QGY-7703 cells was 80-90% for early stage of tumor, whereas it decreased sharply to a very low level of about 10-15% for later stage of tumor, especially when the tumor developed to a visible solid tumor masses, suggesting a better therapeutic effect can be achieved by treatment of adenovirus at early stage.
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay Formalin-fixed sections (5 mm) from tumors of treated mice were deparaffinized in xylene and were hydrated in graded ethanol. The TUNEL-positive cells were identified using the in situ Cell Apoptosis Detection Kit (Promega). For each section, images at Â 400 were obtained.
Immunohistochemistry of the tissue samples
Tissues were formalin-fixed, embedded in paraffin, sectioned and subjected to immunohistochemical staining. A preheat-induced epitope retrieval step was performed in a 0.1 mol/l trisodium citrate solution for 2 min in a conventional pressure cooker. After incubation, sections were immunostained with anti-flag antibody for 1 h at 371C. The secondary AP-conjugated antibody was incubated in the same dilution buffer for 30 min. The peroxidase activity was then visualized with substrate by microscope followed by counterstaining with hematoxylin.
Statistical methods used in this study
Differences of tumor sizes among Ad-GFP, Ad-wt-SVV and Ad-SVV-D53A or PBS-treated groups were assessed by two-way ANOVA. Statistically significant difference was determined when P-value was less than 0.05. Tumor volumes were measured every 3 or 7 days and were presented as means7s.e.m. (n ¼ 6). Survival days of i.p. tumor-bearing mice were compared by Logrank-test; Po0.05 was considered statistically significant.
Results
Generation of recombinant adenoviruses expressing a dominant-negative Survivin-D53A Survivin gene
We generated a recombinant adenovirus Ad-SVV-D53A using homologous recombination in bacteria as described. 12, 16 Briefly, pAdTrack-CMV containing Survivin mutant gene SVV-D53A and pAdEasy-1 vector (Qbiogene) were co-transformed into BJ5183 Escherichia coli and selected on kanamycin for the recombinant plasmid ( Figure 1a) . The resultant pHomo-GFP-CMV-flag-SVV-D53A construct was linearized with Pac I and subsequently transfected into 293A cells for virus production. As SSV-D53A is a point mutation, which differs merely by a single base pair mutation from the wt-Survivn, and thereby both mutant SSV-D53A and wt-SSV in pAdTrack-CMV or in final recombinant vector pHomo-CMV were sequenced before transfection. Viral particles were amplified and purified by band on CsCl. The maximal titer of our Ad-SVV-D53A that has been reached is approximately 5 Â 10 8 GFU/ml determined by TCID50 in 293A cells. The titer of each batch used in experiments was adjusted to the same level of 2.5 Â 10 8 GFU/ml. No significant RCA was detected in our adenoviral preparations (o1 RCA/10 9 GFU). Western blotting comparing expression of the SVV in nontransducted QGY-7703 cells, SVV and SVV-D53A in Ad-SVV and Ad-SVV-D53A-transducted cells performed with an anti-SVV antibody is shown in Figure 1b transducted with Ad-SVV-D53A showed decreased DNA content in G1 and G2 and the increased sub-G1 apoptotic peak. Sub-G1 content gradually increased during 36 h of transfection and by 72 h post-transfection, more than 40% of DNA from total cells examined was represented by fragmented sub-G1 DNA. As a control, Ad-GFP-transducted QGY-7703 cells showed only 11% of background hypodiploid cells underwent apoptosis. As expected, Ad-wt-SVV-transducted QGY-7703 cells were more resistant to apoptosis than Ad-GFP or Ad-SVV-D53A-transducted cells, and at 72 h postincubation, less than 2% of sub-G1 DNA was measured in QGY-7703 transducted with Ad-wt-SVV, indicating that Ad-SVV-D53A is potent to induce apoptosis in cultured tumor cells. Similar results were obtained from human cervical carcinoma HeLa cells (p53 nonfunctional due to Human Papilloma viral protein E6 degradation 18 ), which is not unexpected as we have previously demonstrated that SVV-D53A-induced apoptosis is in a p53-independent fashion. 10 To test whether Ad-SVV-D53A was able to induce apoptosis in more cancer cell lines, two prostate cancer cell lines (DU145 and LNCAP) and three lung cancer cell lines (H1299, H460 and A549) were analysed by MTT assays for cell viability after adenoviruses transfection. As shown in Figure 2c , Ad-SVV-D53A was shown to reduce the cell viability in all the cell lines tested.
To further understand whether Ad-SVV-D53A-induced cell death in QGY-7703 is through mitochondrialmediated pathway involving caspase-9 activation and further PARP-1 cleavage, Western blotting was performed. QGY-7703 cells were first transducted with Ad-GFP, Ad-wt-SVV or Ad-SVV-D53A at 50 MOI individually and 72 h post-transfection; cells were harvested and subjected to Western blot analysis. As shown in the Figure 2d , upper panel, procaspase-9 (45 kDa) was processed into p37 and p35 active forms only in Ad-SVV-D53A-transducted cells, but not in Ad-GFP or Ad-wt-SVV-transducted cells. Correspondingly, the further downstream proteolytic cleavage of the PARP into -85 kDa protein fragment was only observed in Ad-SVV-D53A-transducted cells (Figure 2d, middle panel) . Taken together, these data demonstrated that Ad-SVV-D53A-induced apoptosis is through a mitochondria-mediated apoptotic pathway. To give more strength and validity to Ad-SVV-D53A, cytotoxic effect of Ad-SVV-D53A against normal cells was additionally investigated. Human primary fibroblast cells HF-B were transducted by complexes of Lipofectamine 2000 with adenoviruses at MOI 100:1 owing to its low transfection efficiency. 19, 20 Human normal endothelial cells ECV304 and human liver cancer cells QGY-7703 were also transducted with adenovirus. The percentage of survival for Ad-SVV-D53A-transducted HF-B and ECV304 cells was about 80% at 72 h post-transfection, whereas cell viability of Ad-SVV-D53A-transducted QGY-7703 cells was only 55%, confirming that Ad-SVV-D53A causes less toxicity to normal cells. Data were presented as means7s.e.m. as shown in Figure 2e . The kinetic graph showed that the tumor size of Ad-wt-SVV group was always a fold higher than that of mock or Ad-GFP group. The mock or Ad-GFP-transducted group exhibited the same development pattern and did not differ significantly (P40.05) as shown in Figure 3 . We noticed that all the animals that received Ad-SSV-D53A-transducted cells were devoid of visible solid tumors.
Next, we sought to determine whether a direct intratumoral injection of Ad-SVV-D53A could potentially inhibit the tumor growth. Exponentially growing QGY-7703 (4 Â 10 6 ) cells were first injected into the left flank of animals. Mice were divided into three experimental groups with eight mice per group. At day 3 postimplantation of the tumor cells all mice received intratumoral treatment with same numbers of viral particles (2.5 Â 10 7 GFU/100 ml) of Ad-GFP, Ad-wt-SVV and Ad-SVV-D53A, respectively. These procedures of adenoviral injection were repeated five times. Mice were monitored for appearance of visible tumors and tumor volumes were calculated weekly using the formula 0.4(ab 2 ), where a represents the long measured axis of the tumor; and b the short measured axis of the tumors. 21 After intratumoral adenoviral injection, only 6/8 mice in Ad-SVV-D53A and Ad-GFP groups were found to develop tumors at day 9, whereas 8/8 mice in Ad-wt-SVV-treated group developed tumors. The time course for comparison of tumor volumes after five consecutive intratumoral injections with three different adenoviral . Mice were killed 48 h after the last (the 5th) injection and tissues sections (5 mm thick) were used for H&E staining, in situ apoptosis analysis (transferase-mediated dUTP nick-end labeling (TUNEL) assay) and immunohistochemical study as shown in b. Anti-flag antibody was used in immunohistochemical staining for detection of adenoviraldelivered expression of Survivin.
Ad-SVV-D53A-mediated gene therapy D-E Zhu et al treatment including Ad-GFP, Ad-wt-SVV and Ad-SVV-D53A was shown in Figure 4a . From this figure, we noticed that starting from week 3, tumor treated with Ad-SVV-D53A was much smaller in size than that treated with Ad-GFP or Ad-wt-SVV. By the end of the fifth week, animals were killed and tumors were resected and compared (data not shown); the median volume of Ad-SVV-D53A-treated tumor was only about one-fifth of that of the Ad-GFP-treated tumor. It is interesting to note that xenografts treated with Ad-wt-SVV were much larger than those treated with Ad-GFP or Ad-SVV-D53A. This may be a result of antiapoptotic function of overexpression wild-type surviving.
The expression and therapeutic efficacy of adenoviralmediated SVV-D53A gene transfer were also studied in tumor tissue sections. To verify whether the molecular mechanism underlying the failure of tumor formation and tumor growth inhibition is because of the proapoptotic activity of SVV-D53A, we performed both H&E staining and TUNEL assay. Mice were divided into three groups (six mice/group), and implanted with 4 Â 10 6 QGY-7703 cells into hind flank region. Each of the animals then received five consecutive (days 8, 10, 12, 14 and 16) treatments with respective adenoviral particles, including Ad-GFP, Ad-wt-SVV and Ad-SVV-D53A (2.5 Â 10 7 GFU/100 ml) intratumorally. By the end of day 18, animals were killed and tumors were excised, fixed and stained with H&E. Experiments were performed in triplicate and only one representative H&E staining result was shown. Compared with the Ad-GFP and Adwt-SVV treatment, sections from the Ad-SVV-D53A treated group which showed pyknotic nuclei characteristic of apoptosis morphological feature under the light microscope ( Â 400). (Figure 4b, upper panel) . The mean percentage of TUNEL-positive cells (nuclei) in the total cell count is approximately 1675%. Those labeled cells showed brown spots scattered randomly throughout the tumor tissue section derived from Ad-SVV-D53A-treated animals, indicative of DNA fragmentation as shown in the middle panels of Figure 4b . In contrast, few signs of DNA fragmentation were detected in the tumor tissue section obtained from animals that received Ad-GFP and Ad-wt-SVV treatment. Collectively, these data suggest that regression of QGY-7703 tumor growth in nude mice via adenoviral-mediated treatment may result from an apoptotic inducement by SVV-D53A. To further determine the existence of overexpression of wt-SVV and SVV-D53A in transducted cells, tissue sections were examined by immunohistochemistry. Tissues were formalin-fixed, embedded in paraffin, sectioned and subjected to immunohistochemical staining with anti-flag antibody, followed by counterstaining with hematoxylin. The reason for not using anti-SVV antibody, rather antiflag antibody was to specifically examine adenoviral-mediated Survivin, not the endogenous Survivin. As shown in the lower panel of Figure 4b , brown spots representing the overexpression of Flag-wt-SVV and Flag-SVV-D53A were detected only in Ad-wt-SVV-and Ad-SVV-D53A-transducted tumor cells, but not in Ad-GFP-transducted cells.
Ad-Survivin-D53A intraperitoneal treatment significantly increases duration of survival in mice bearing intraperitoneal tumors To determine the effect of adenoviral-mediated delivery of SVV-D53A on the survival duration of nude mice inoculated with hepatocarcinoma cells, freshly harvested QGY-7703 cultured cells were injected into the peritoneum of a total of 18 female athymic nude mice on day 0 (4 Â 10 6 cells/mouse) and all implanted nude mice were randomly divided into three groups (six each). Treatment of Ad-GFP, Ad-wt-SVV or Ad-SVV-D53A was given to each group, respectively, by five consecutive i.p. injections (2.5 Â 10 7 GFU/100 ml) on days 4, 6, 8 10 and 12. The mice were monitored daily for clinical signs of tumor in the peritoneal cavity, and were removed either after they died naturally or exhibited extremely heavy tumor burden following the Institutional guidelines for animal care. Survival times were determined by the Kaplan-Meier method 22 using Graphpad prism software. As shown in Figure 5 , the median survival time of Ad-wt-SVV-treated group was 32.5 days, whereas that of Ad-GFP-treated group was 34.5 days. In contrast, the median survival of Ad-SVV-D53A group was 54.5 days which was significant (Po0.05) when compared with the other Ad-GFP or Adwt-SVV treated groups. Although enhanced expression of wt-SSV was shown to increase tumorigenicity in the tumor xenografts ( Figure 3 and 4) , ectopic expression of Survivin in QGY-7703 i.p. did not significantly shorten the animal survival when compared to the mock-treated animals. The explanation for this discrepancy is beyond the scope of this study. However, we believe that different sites for transplantation of tumor cells (s.c. vs i.p.) and/or different delivery pathways into nude mice (intratumoral vs i.p.) might account for this dissimilarity. Ad-SVV-D53A-mediated gene therapy D-E Zhu et al
Discussion
Survivin, a member of IAP family has attracted increasing attention owing to its important role implicated in cancer diagnosis and cancer treatment. [23] [24] [25] Unregulated Survivin expression has been identified in different cancer patients and in the majority of tumors, which is an intriguing feature that helps to differentiate between normal and cancer tissues. [26] [27] [28] [29] [30] Moreover, Survivin expression is correlated with clinical progression, and resistance to chemo-and radiotherapy. 31 Thus, it may suggest that Survivin could be a universal tumor antigen and a rational target for cancer therapies. To alter the Survivin pathway may be a good choice for targeting a wide variety of tumors. Earlier studies have demonstrated that suppression of Survivin by a dominant-negative mutant or siRNA causes spindle catastrophe and promotes apoptosis. 32, 33 Powerful RNA interference techniques used for targeting Survivin has previously been performed. Kappler et al. 34 reported that Survivinspecific siRNA could be a selective treatment to kill sarcoma cells, regardless of the presence or absence of wtp53 alleles. Lens et al. 35 had also reported that siRNA against Survivin could cause polyploidy, which resulted in incomplete cytokinesis. Moreover, Uchida et al. 36 had constructed the Survivin-specific siRNA into the adenoviral vector Ad-siSVV. This Ad-siSVV successfully exerted a gene knockdown effect and induced apoptosis in HeLa, U251 and MCF-7 cells. Intratumoral injection of Ad-siSVV significantly suppressed tumor growth in a xenograft model using U251 glioma cells. Adenoviral vectors are still widely used as gene transfer vectors because of not only their ability to deliver target genes into a broad range of host tissues but also their ability to infect both proliferating and nonproliferating cells. 11 In the present study, we have developed a novel adenoviral vector expressing SVV-D53A, which was shown to induce apoptosis in seven different cell lines. In this study, we chose a human hepatocarcinoma cell line QGY-7703 as a cell model, because we had detected that in QGY-7703, Survivin displayed much higher level than that in other tumor cell lines, such as HeLa cells. Despite that various Survivin-targeting techniques has been reported, as a supplementary investigation, our successful targeting strategy using novel Survivin dominant-negative mutant mediated by adenoviral vector added an alternative approach to a growing list of Survivin gene therapeutic strategies.
We have demonstrated previously that SVV-D53A can interact with wt-SSV to form a SVV*SVV-D53A heterodimer or with itself to form a mutant homodimer. Any Survivin dimer containing SVV-D53A is unable to bind Smac/DIABLO, thus abolishing the capability of Survivin to restore the prevention of caspase activation by XIAP. 10 In order to investigate the therapeutic potential of SVV-D53A, we investigated that Ad-SVV-D53A inhibit tumor cells growth both in vitro and in vivo. Implanted Ad-SVV-D53A-transducted QGY-7703 was unable to establish tumor outgrowth, whereas Ad-GFP-or Ad-wt-SVVtransducted cells were able to develop solid tumors.
These in vivo data were in agreement with our in vitro results from colony formation assay, in which, Ad-wt-SVV and Ad-GFP, but not Ad-SVV-D53A-transducted QGY-7703 cells, were able to form colonies in soft agarose (data not shown).
It was quite obvious that Ad-SVV-D53A intratumoral injection caused a significant regression of tumor volume compared with injection of Ad-GFP or Ad-wt-SVV. The regression in tumor volume was found to be associated with the apoptotic activity of the Ad-SVV-D53A, which was supported by the data from both the in vivo TUNEL assays and in H&E staining experiments. A high correlation was observed between the manifestation of pyknotic nuclei in H&E-staining and the identification of DNA fragmentation by TUNEL technique (Figure 4b ). QGY-7703 cells transducted with adenovirus expressing wt-SSV greatly increased its tumorigenicity in tumor xenografts (Figure 3) , whereas in the mice survival experiment, i.p. tumor-bearing mice treated with Ad-wt-SVV did not significantly reduce the survival duration when compared with Ad-GFP-treated mice. This may be explained by the fact that s.c. implants are much simpler than i.p. situation, where potent tumorigenicity of Survivin might be counteracted by yet unknown and complicated factors in experimental mice.
In conclusion, the results from this study demonstrate that adenoviral delivery of SVV-D53A, a novel Survivin dominant-negative mutant gene, is capable of suppressing QGY-7703 tumor cell growth both in vitro and in vivo, which might have a potential therapeutic utility in treating aggressive liver carcinomas.
